Pfizer licenses neratinib to newly created Puma Biotechnology
Executive Summary
Cancer-focused start-up Puma Biotechnology Inc. has picked up its first compound by licensing worldwide development and commercialization rights to Pfizer Inc.’s neratinib, a Phase III tyrosine kinase inhibitor for HER2-positive breast cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice